PDF(Pubmed)
Abstract：
UNASSIGNED: Dry eye disease (DED) is a prevalent condition causing ocular discomfort and visual disturbances, often managed with artificial tears. This study aimed to assess and compare the efficacy of eye drops containing Crosslinked Hyaluronic Acid (CHA) with liposomes and crocin and standard Hyaluronic Acid (HA) for DED management.
UNASSIGNED: A single-blind, longitudinal study was conducted on 24 participants (48 eyes), randomized to receive one of the two treatments. Ocular health measures, including the ocular surface disease index (OSDI) and the standard patient evaluation of eye dryness (SPEED) scores, were assessed at baseline and 6 weeks post-treatment using the Ocular Surface Analyzer.
UNASSIGNED: CHA achieved a lipid layer thickness increase of 1.29 ± 1.08 Guillon pattern degree (p < 0.01), FNIBUT increase 0.64 ± 0.77 s (p < 0.01), MNIBUT increase1.28 ± 4.74 s (p = 0.19), OSDI decrease 11.72 ± 6.73 score points (p < 0.01) and SPEED decrease 1.16 ± 5.05 score points (p = 0.27). Significant reductions in the OSDI and SPEED scores post-treatment were observed with both treatments, indicating their effectiveness.
UNASSIGNED: CHA with liposomes exhibits superior efficacy compared to standard HA eye drops in the management of DED. These findings highlight the potential for personalized treatment strategies incorporating CHA, indicating a more effective approach to DED management. However, further research is required to validate these results and investigate the long-term effects, which may pave the way for a data-driven and optimized approach to managing DED.
UNASSIGNED: A single-blind, longitudinal study was conducted on 24 participants (48 eyes), randomized to receive one of the two treatments. Ocular health measures, including the ocular surface disease index (OSDI) and the standard patient evaluation of eye dryness (SPEED) scores, were assessed at baseline and 6 weeks post-treatment using the Ocular Surface Analyzer.
UNASSIGNED: CHA achieved a lipid layer thickness increase of 1.29 ± 1.08 Guillon pattern degree (p < 0.01), FNIBUT increase 0.64 ± 0.77 s (p < 0.01), MNIBUT increase1.28 ± 4.74 s (p = 0.19), OSDI decrease 11.72 ± 6.73 score points (p < 0.01) and SPEED decrease 1.16 ± 5.05 score points (p = 0.27). Significant reductions in the OSDI and SPEED scores post-treatment were observed with both treatments, indicating their effectiveness.
UNASSIGNED: CHA with liposomes exhibits superior efficacy compared to standard HA eye drops in the management of DED. These findings highlight the potential for personalized treatment strategies incorporating CHA, indicating a more effective approach to DED management. However, further research is required to validate these results and investigate the long-term effects, which may pave the way for a data-driven and optimized approach to managing DED.
摘要：
■干眼病（DED）是一种引起眼部不适和视觉障碍的常见病，经常用人工泪液管理。本研究旨在评估和比较含有交联透明质酸（CHA）与脂质体和crocin和标准透明质酸（HA）的滴眼液用于DED管理的功效。
■单盲，对24名参与者(48只眼)进行了纵向研究，随机接受两种治疗之一。眼部健康措施，包括眼表疾病指数（OSDI）和标准患者眼干评估（SPEED）评分，在基线和治疗后6周使用眼表分析仪进行评估。
■CHA实现了脂质层厚度增加1.29±1.08Guillon模式度（p<0.01），FNIBUT增加0.64±0.77s(p<0.01)，MNIBUT增加1.28±4.74s(p=0.19)，OSDI降低11.72±6.73分(p<0.01),SPEED降低1.16±5.05分(p=0.27)。两种治疗方法均观察到治疗后OSDI和SPEED评分显着降低，表明其有效性。
■在DED的管理中,与标准HA滴眼液相比,具有脂质体的CHA表现出优异的功效。这些发现凸显了纳入CHA的个性化治疗策略的潜力，表明了一种更有效的DED管理方法。然而,需要进一步的研究来验证这些结果并调查长期影响，这可能为管理DED的数据驱动和优化方法铺平道路。
■单盲，对24名参与者(48只眼)进行了纵向研究，随机接受两种治疗之一。眼部健康措施，包括眼表疾病指数（OSDI）和标准患者眼干评估（SPEED）评分，在基线和治疗后6周使用眼表分析仪进行评估。
■CHA实现了脂质层厚度增加1.29±1.08Guillon模式度（p<0.01），FNIBUT增加0.64±0.77s(p<0.01)，MNIBUT增加1.28±4.74s(p=0.19)，OSDI降低11.72±6.73分(p<0.01),SPEED降低1.16±5.05分(p=0.27)。两种治疗方法均观察到治疗后OSDI和SPEED评分显着降低，表明其有效性。
■在DED的管理中,与标准HA滴眼液相比,具有脂质体的CHA表现出优异的功效。这些发现凸显了纳入CHA的个性化治疗策略的潜力，表明了一种更有效的DED管理方法。然而,需要进一步的研究来验证这些结果并调查长期影响，这可能为管理DED的数据驱动和优化方法铺平道路。
